The pre-clinical research poster related to the Company's Oct 31, 2012 PR doesn't just "imply" that Bavi increases M1 polarization, it actually states this as a fact. See notes under the Bavi MOA image at the bottom left of this poster:
Another interesting aspect of the left image in the lower left corner of this poster is that it shows the PD-1 and CTLA-4 markers (which got so much attention and major press coverage at ASCCO this year) as being essentially "down stream" MOAs that stimulate the T-cells as apposed to Bavi's more "upstream" MOA the affects the core of the tumor's immuno-therapeutic stimulatory environment.